Acasti Pharma Inc. (ACST)
NASDAQ: ACST · IEX Real-Time Price · USD
2.760
+0.060 (2.22%)
At close: May 16, 2024, 3:16 PM
2.880
+0.120 (4.35%)
After-hours: May 16, 2024, 4:35 PM EDT
Company Description
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage.
It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
The company was incorporated in 2002 and is headquartered in Laval, Canada.
Acasti Pharma Inc.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Prashant Kohli |
Contact Details
Address: 103 Carnegie Center, Suite 300 Princeton, New Jersey 08540 United States | |
| Phone | 609-649-9272 |
| Website | acastipharma.com |
Stock Details
| Ticker Symbol | ACST |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001444192 |
| CUSIP Number | 00430K402 |
| ISIN Number | CA00430K8656 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Prashant Kohli | Chief Executive Officer and Director |
| Robert J. DelAversano CPA | Principal Financial and Accounting Officer |
| Dr. R. Loch MacDonald M.D., Ph.D. | Member of Scientific Advisory Board and Chief Medical Officer |
| Amresh Kumar Ph.D. | Vice President of Program Management |
| Carrie D'Andrea | Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 1, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | 8-K | Current Report |
| Feb 12, 2024 | 10-Q | Quarterly Report |
| Jan 8, 2024 | 8-K | Current Report |
| Dec 15, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 10-Q | Quarterly Report |
| Oct 23, 2023 | 8-K | Current Report |